What is the purpose of the study?
COVID-19 is thought to lead to depression by causing inflammation, the body's natural response to injury and infection, in the brain. We have developed a brain scan to detect inflammation and we have used it to study many different illnesses. In this study, we plan to use this scan to look at brain inflammation in those experiencing depression after contracting COVID-19. We hope that results from this study will lead to new treatments specifically for depression caused by inflammation.
Who is needed?
- Individuals with post COVID-19, new onset depression
- Individuals without a mental health or addiction problem
Age range: 18 - 75
Gender: All
Ethnicity: All
What does the study involve?
- Number of contacts: 1 phone call, 3 or 4 sessions at CAMH
- Time period: 4 - 6 weeks
- Length of contacts: 20 min. phone call, 4-hour session, 6-hour session, 6-hour session, 2-hour session
- Treatment offered: No
Study Location(s):
250 College St., Research Imaging Centre
Investigator(s): Dr. Jefferey Meyer
Contact Information:
- Phone: 416-535-8501 ext.39674
- E-mail: COVID19study@camh.ca
Study End Date: 31 December 2026
REB number: 2022/201
Full Study Title: Presynaptic Imaging in Major Depressive Episodes After COVID-19
PLEASE NOTE:
- Research staff cannot give medical advice over the phone.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.